As investors look ahead to results later this year from the second phase III trial with Rigel Pharmaceuticals Inc.'s fostamatinib, principal investigator James Bussel said "the fact that, at least so far, the results in this [first] phase III trial mimic and are very similar to the first phase II trial gives all of us on the Rigel team a lot of confidence."